Par Pharmaceutical, Inc. v. Novartis AG

Par Pharmaceutical, Inc. v. Novartis AG

P.T.A.B. (2016)

Fitzpatrick Scores Win On Behalf Of Novartis In Inter Partes Review Proceeding Concerning Novartis's Zortress® Product

On April 28, 2016, Christopher Loh, Corinne Atton and Nicholas Kallas of Fitzpatrick prevailed on behalf of their client, Novartis AG, in a proceeding before the Patent Trial and Appeal Board (PTAB) concerning Novartis’s U.S. Patent No. 6,455,518. In that proceeding, Par Pharmaceutical, Inc. petitioned the PTAB to initiate an inter partes review challenging the validity of claim 7 of the ’518 patent, directed to a method of preventing transplant rejection by co-administering drugs including Novartis’s Zortress® (everolimus). Following the submission of Novartis’s preliminary response, the PTAB on April 28, 2016 issued a non-appealable decision denying Par’s petition, explaining that it was persuaded by Novartis’s arguments that the prior art insufficiently discloses an element of the challenged claim, and therefore that there was no “reasonable likelihood that Par will prevail.”